februari
may
novel
avian
influenza
viru
associ
human
case
includ
death
occur
mainli
eastern
china
report
infect
present
sever
clinic
pictur
character
bilater
pneumonia
progress
acut
respiratori
distress
syndrom
associ
cytokin
storm
multiorgan
failur
clinic
present
similar
infect
unusu
virus
caus
mostli
mild
respiratori
ill
conjunct
hospit
case
fatal
rate
estim
compar
season
influenza
infect
howev
mild
case
infect
recent
detect
sentinel
influenzalik
ill
surveil
suggest
could
caus
substanti
number
asymptomat
moder
infect
line
infect
influenza
viru
strain
except
report
laboratoryconfirm
mild
case
infect
epidemiolog
differ
includ
rapid
accumul
human
infect
differ
age
distribut
infect
individu
infect
occur
mostli
children
young
adult
case
individu
older
year
sequenc
analysi
indic
origin
multipl
reassort
event
avian
influenza
virus
howev
sequenc
bear
sever
genet
marker
human
adapt
includ
hemagglutinin
ha
consequ
mutat
host
respons
assess
previou
studi
virushost
interact
focus
transmiss
ha
bind
properti
strain
mix
receptor
prefer
associ
capac
effici
transmit
direct
contact
poorli
respiratori
droplet
ferret
model
properti
intermediari
human
season
influenza
virus
prefer
effici
transmit
respiratori
droplet
virus
prefer
transmit
effici
either
respiratori
droplet
directcontact
transmiss
model
crystallograph
structur
ha
strain
isol
human
patient
show
increas
avid
human
receptor
compar
avian
viru
due
mutat
assay
ha
bind
human
tissu
section
reveal
intermedi
bind
pattern
human
iav
preferenti
bind
noncili
cell
apic
region
trachea
bind
alveolar
section
addit
singl
mutat
substanti
increas
ha
bind
human
receptor
human
respiratori
tract
great
concern
potenti
adapt
human
acquisit
sustain
persontoperson
transmiss
addit
recent
studi
point
acquir
resist
neuraminidas
na
inhibitor
hospit
patient
treat
oseltamivir
peramivir
emerg
viru
resist
neuraminidas
inhibitor
concern
sinc
viru
also
natur
resist
ion
channel
blocker
vaccin
yet
avail
studi
appli
global
transcriptom
profil
human
cell
infect
avian
human
iav
broadli
character
host
respons
infect
quickli
identifi
fdaapprov
drug
may
act
antivir
show
induc
specif
respons
respons
intermedi
avian
notabl
induc
downregul
antigen
present
pathway
delay
proinflammatori
cytokin
induct
greater
extent
could
import
impact
vivo
immun
respons
similar
induc
minor
chang
eicosanoid
signal
gene
implic
chromatin
modif
final
comput
predict
sever
fdaapprov
drug
abl
revers
host
respons
may
antivir
emerg
viru
one
drug
minocyclin
exhibit
activ
vitro
polar
human
bronchial
epitheli
cell
possess
multipl
featur
vivo
airway
epithelium
use
previous
vitro
model
multipl
studi
influenza
virushost
interact
studi
respiratori
virus
polar
confluent
monolay
cell
infect
apic
avianorigin
iav
human
season
viru
multipl
infect
moi
viral
replic
assess
h
postinocul
hpi
standard
plaqu
assay
shown
fig
replic
level
similar
hpi
iav
hpi
titer
slightli
lower
iav
hpi
reach
slightli
higher
peak
hpi
averag
number
pfuml
iav
cytopath
effect
destruct
cell
monolay
observ
hpi
human
avian
iav
limit
extent
infect
iav
assess
whole
transcriptom
cellular
respons
iav
infect
use
sever
metric
fig
first
multidimension
scale
md
use
visual
euclidian
distanc
transcriptom
profil
two
dimens
fig
plot
sampl
repres
dot
sampl
similar
transcriptom
profil
ie
small
euclidian
distanc
close
togeth
increas
distanc
rel
increas
transcriptom
dissimilar
observ
sampl
cluster
time
point
viral
treatment
indic
good
agreement
biolog
replic
hpi
iavinfect
sampl
similar
mockinfect
one
mock
suggest
transcriptom
chang
earli
infect
distanc
mock
increas
hpi
hpi
viral
condit
distinct
locat
indic
specif
respons
iav
howev
avian
sampl
rel
close
togeth
sampl
locat
rel
far
iav
indic
specif
host
respons
viru
determin
whether
host
respons
infect
closer
avian
human
iav
respons
measur
transcriptom
distanc
iavinfect
sampl
time
point
fig
hpi
significantli
closer
surprisingli
hpi
shortest
distanc
largest
distanc
indic
respons
distinct
note
respons
infect
differ
mock
sampl
avian
iav
hpi
suggest
specif
respons
infect
final
determin
transcriptom
distanc
iav
mockinfect
sampl
time
point
use
hierarch
cluster
fig
analysi
confirm
induc
largest
host
respons
earli
infect
hpi
respons
similar
respons
closer
altogeth
result
show
host
respons
highli
specif
viru
global
similar
respons
iav
hpi
interestingli
although
similar
ha
sequenc
host
respons
two
virus
differ
studi
specif
host
respons
iav
identifi
gene
differenti
express
de
iavinfect
sampl
mockinfect
sampl
time
point
use
follow
criteria
q
valu
determin
limma
empir
bay
moder
test
fold
chang
valu
fig
consist
transcriptom
distanc
analysi
iav
induc
transcriptom
chang
hpi
fig
hpi
respons
infect
quit
robust
de
gene
de
gene
infect
respect
hpi
iav
induc
drastic
host
respons
number
de
gene
rang
gene
gene
gene
de
gene
hpi
amplitud
host
respons
hpi
closer
human
avian
iav
fig
therefor
observ
progress
host
respons
human
infect
wherea
avian
iav
delay
host
respons
hpi
massiv
dysregul
host
respons
observ
respons
character
number
de
gene
intermedi
avian
human
iav
total
gene
de
least
one
viral
treatment
one
time
point
fig
gene
defin
whether
gene
downregul
cours
infect
minor
gene
transient
express
pattern
use
de
profil
de
gene
group
cluster
function
enrich
perform
cluster
tabl
see
also
fig
supplement
materi
total
de
gene
specif
infect
gene
chang
respons
cluster
gene
gene
dysregul
iav
except
cluster
gene
gene
specif
induc
broadli
enrich
among
gene
implic
global
regul
gene
transcript
cell
cycl
tabl
see
also
fig
supplement
materi
interestingli
top
predict
regul
cluster
mll
histon
methyltransferas
involv
epigenet
regul
divers
gene
type
associ
cell
cycl
regul
develop
tabl
regul
transcript
cell
cycl
could
relat
specif
interact
protein
nuclear
factor
among
gene
significantli
upregul
iav
except
cluster
sever
interferon
ifn
type
gene
see
fig
cytokin
induc
iav
belong
cluster
howev
closer
examin
cytokin
induct
level
reveal
earlier
stronger
induct
infect
avian
iav
especi
see
fig
among
avian
iav
level
cytokin
includ
significantli
lower
respons
infect
infect
see
fig
whole
de
gene
list
chang
similarli
respons
virus
includ
gene
downregul
similarli
virus
cluster
gene
gene
similarli
unchang
avian
iav
infect
dysregul
infect
cluster
gene
cluster
particularli
interest
sinc
includ
sever
gene
antigen
present
pathway
upregul
infect
includ
encod
class
major
histocompat
complex
mhc
molecul
hlaa
hlab
hlaf
transcript
factor
ciita
gene
belong
antigen
present
pathway
also
found
cluster
downregul
infect
upregul
cell
includ
gene
encod
class
ii
mhc
molecul
hladra
see
fig
supplement
materi
final
de
gene
similar
profil
iav
versu
iav
gene
significantli
de
infect
cluster
gene
gene
could
reflect
adapt
human
host
similar
find
season
viru
cluster
gene
significantli
upregul
sampl
includ
gene
eicosanoid
signal
pathway
see
fig
supplement
materi
upstream
pathway
gene
express
level
time
increas
infect
hpi
encod
phospholipas
enzym
catalyz
arachidon
acid
product
key
inflammatori
intermedi
catalyz
differ
lipid
mediat
regul
mani
biolog
process
includ
inflamm
immun
function
sever
receptor
eicosanoid
also
increas
iav
fortyseven
gene
cluster
involv
chromatin
modif
major
gene
involv
biolog
process
similar
profil
versu
gene
specif
upregul
sampl
cluster
gene
see
fig
could
reflect
humaniavlik
abil
modifi
express
gene
involv
chromatin
epigenet
regul
conclus
cluster
analysi
reveal
extens
list
function
dysregul
specif
similar
find
iav
includ
proinflammatori
cytokin
antigen
present
pathway
sever
nuclear
pathway
confirm
transcriptom
distanc
analysi
similar
respons
cluster
specif
virus
cluster
sinc
gene
de
specif
respons
previous
shown
drug
revers
host
respons
iav
coronaviru
infect
may
inhibit
viral
replic
effort
identifi
potenti
antivir
target
cellular
respons
iav
use
two
independ
complementari
method
first
method
literaturebas
predict
use
ingenu
knowledg
databas
identifi
molecul
known
regul
de
gene
opposit
direct
z
score
iav
infect
fig
iav
potenti
antivir
identifi
upstream
regul
signific
z
score
least
time
point
posit
z
score
time
point
drug
identifi
potenti
therapi
compound
identifi
potenti
regul
respons
iav
thirteen
compound
identifi
neg
regul
respons
includ
sever
kinas
inhibitor
genistein
jak
inhibitor
immunosuppress
drug
cyclosporin
fontolizumab
infliximab
etanercept
one
antibiot
minocyclin
drug
predict
antivir
lower
z
score
includ
chloroquin
aspirin
resveratrol
confirm
predict
use
second
independ
method
datadriven
predict
base
connect
map
cmap
cmap
databas
gene
express
profil
repres
compound
use
identifi
drug
revert
iav
signatur
cmap
score
close
induc
chang
similar
induc
iav
cmap
score
close
fig
cmap
profil
gener
use
cell
line
array
platform
differ
experi
use
result
second
line
valid
consid
drug
predict
ingenu
pathway
knowledg
base
ipa
among
compound
predict
upstream
regul
least
iav
found
signific
cmap
relationship
drug
viral
condit
depict
drugviru
network
fig
result
confirm
genistein
revert
host
respons
iav
convers
resveratrol
found
induc
gene
express
chang
similar
induc
iav
troglitazon
predict
revers
signatur
across
infect
posit
cmap
score
viral
treatment
hpi
troglitazon
hpi
final
drug
strainspecif
effect
minocyclin
predict
ipa
cmap
neg
regul
signatur
simvastatin
induc
effect
opposit
altogeth
combin
two
differ
approach
identifi
kinas
inhibitor
genistein
capabl
revers
host
respons
test
iav
includ
addit
molecul
identifi
method
revert
signatur
troglitazon
minocyclin
valid
drug
predict
evalu
abil
minocyclin
tetracyclin
inhibit
viral
replic
vitro
molecul
chosen
predict
revers
signatur
comput
method
test
previous
influenza
viru
use
colorimetr
viabil
assay
cytotox
concentr
minocyclin
cell
evalu
around
observ
signific
cytotox
see
fig
supplement
materi
evalu
potenti
antivir
effect
minocyclin
polar
cell
pretreat
increas
concentr
minocyclin
h
infect
moi
fig
hpi
signific
decreas
viral
titer
cell
treat
minocyclin
p
lower
concentr
minocyclin
inhibit
viral
replic
ribavirin
antivir
drug
vitro
activ
dna
rna
virus
use
posit
control
induc
robust
decreas
viral
titer
fig
overal
data
show
minocyclin
exert
modest
signific
antivir
effect
valid
silico
drug
screen
although
outbreak
enter
stationari
state
china
case
report
sinc
late
may
concern
may
reappear
winter
avian
iav
inde
season
pattern
increas
human
infect
winter
addit
like
still
circul
poultri
sever
studi
shown
possess
genet
marker
associ
adapt
human
allow
higher
replic
mammal
cell
increas
bind
human
receptor
ha
adapt
human
concern
sinc
could
lead
effici
humantohuman
transmiss
studi
shown
cell
respons
infect
similar
infect
infect
avian
virus
impli
adapt
human
host
human
iavlik
transcriptom
respons
relat
similar
lower
induct
sever
gene
involv
eicosanoid
pathway
lipid
mediat
pathway
recent
identifi
correl
pathogen
resolut
phase
iav
infect
mice
antivir
effect
cell
mice
analysi
reveal
eicosanoid
pathway
differenti
regul
avian
human
iav
potenti
impact
lung
inflamm
viral
replic
importantli
differ
transcriptom
respons
infect
relat
major
differ
replic
virus
previous
observ
higher
replic
strain
season
viru
cell
howev
higher
moi
use
replic
similar
replic
avian
human
iav
observ
surprisingli
distinct
respons
despit
genet
similar
ha
segment
therefor
analysi
viral
sequenc
alon
predict
host
respons
infect
analysi
ha
human
receptor
reveal
profil
intermedi
human
avian
iav
observ
host
respons
share
similar
respons
human
avian
iav
also
observ
larg
amount
specif
cell
respons
infect
gene
significantli
induc
involv
cell
cycl
regul
transcript
epigenet
modif
consist
find
previou
studi
polar
cell
note
avian
iav
induc
weaker
proinflammatori
cytokin
respons
human
iav
gene
code
type
ifn
cytokin
reduc
cytokin
induct
even
strike
sampl
abil
delay
antivir
host
respons
could
also
major
impact
vivo
pathogenesi
human
infect
final
gene
code
antigen
present
pathway
protein
upregul
cell
express
gene
either
unchang
avian
iav
downregul
viru
notabl
downregul
antigen
present
pathway
also
observ
nonpolar
cell
infect
avian
viru
upregul
follow
human
infect
alpha
ifn
treatment
v
menacheri
j
eisfeld
l
josset
c
sim
g
katz
kawaoka
r
baric
unpublish
data
therefor
downregul
absenc
induct
antigen
present
infect
epitheli
cell
characterist
avian
versu
human
iav
given
concern
immunogen
avian
virus
mechan
antigen
present
pathway
control
implic
vivo
warrant
explor
vaccin
prevent
infect
current
avail
prophylaxi
treatment
reli
antivir
studi
mice
patient
shown
low
efficaci
na
inhibitor
morbid
moreov
emerg
viru
resist
na
inhibitor
observ
one
resist
mutat
induc
highlevel
oseltamivir
resist
without
impair
viral
replic
vivo
virul
final
ribavirin
show
vitro
activ
influenza
virus
includ
current
approv
treatment
influenza
controversi
efficaci
vivo
develop
altern
antivir
therapeut
therefor
prioriti
genomebas
drug
repurpos
strategi
reli
identif
drug
revers
cell
respons
viral
infect
success
identifi
antivir
iav
coronaviru
strategi
advantag
abl
screen
larg
number
avail
drug
silico
potenti
acceler
use
clinic
use
combin
two
complementari
method
knowledgebas
approach
use
ipa
priorit
drug
publish
effect
opposit
iavinduc
gene
express
chang
databas
approach
use
drug
gene
express
profil
present
cmap
determin
whether
drug
treatment
induc
transcriptom
chang
opposit
viral
infect
twentysix
molecul
predict
first
method
modul
host
respons
least
one
iav
present
cmap
found
induc
gene
express
chang
opposit
iav
signatur
multipl
cell
line
treatment
drug
predict
method
kinas
inhibitor
genistein
antibiot
minocyclin
addit
antidiabet
drug
troglitazon
threshold
ipa
predict
found
cmap
significantli
revert
signatur
hpi
importantli
evalu
activ
minocyclin
tetracyclin
antimicrobi
action
independ
antiinflammatori
neuroprotect
properti
observ
minocyclin
significantli
inhibit
replic
vitro
minocyclin
previous
shown
inhibit
simian
immunodefici
viru
human
immunodefici
viru
siv
hiv
replic
vitro
vivo
reduc
sivinduc
enceph
sever
macaqu
minocyclin
also
shown
inhibit
west
nile
viru
replic
vitro
possibl
inhibit
jun
ntermin
protein
kinas
jnk
induct
protect
mice
japanes
enceph
viru
infect
studi
first
knowledg
show
minocyclin
also
inhibit
influenza
viru
replic
vitro
moreov
assay
valid
silico
drug
predict
minocyclin
interest
candid
consid
vivo
test
sinc
fda
approv
readili
avail
well
toler
addit
minocyclin
antivir
activ
neuroprotect
effect
may
potenti
prevent
influenzaassoci
neurolog
complic
silico
drug
predict
valid
literatur
mine
reveal
drug
predict
effect
least
one
iav
present
studi
alreadi
test
influenza
cell
mous
model
antivir
effect
test
see
tabl
supplement
materi
among
drug
show
effect
influenza
viru
replic
pathogen
dexamethason
predict
potenti
agent
sinc
posit
z
score
infect
earli
time
point
could
therefor
increas
earli
viral
replic
could
link
controversi
role
corticosteroid
patient
influenza
acut
respiratori
distress
syndrom
ard
earli
corticosteroid
therapi
may
harm
like
sever
drug
predict
previous
known
antiiav
effect
may
broad
antivir
effect
could
activ
fdaapprov
drug
alreadi
use
clinic
divers
indic
influenza
identifi
silico
screen
previous
publish
antiinfluenza
effect
chloroquin
particularli
interest
consid
therapeut
intervent
vivo
pulmonari
host
respons
outcom
influenza
infect
determin
directli
transpos
transcriptom
profil
singl
cell
type
wholelung
respons
infect
depend
interact
infect
cell
immun
cell
lung
microenviron
addit
host
respons
influenza
infect
depend
cell
type
differenti
level
infect
cell
highlight
recent
review
novel
mathemat
model
need
model
interact
cell
integr
vitro
vivo
studi
use
multivari
model
approach
mcdermott
et
al
abl
predict
pulmonari
express
conserv
regulatori
modul
macaqu
mice
respons
infect
regulatori
model
built
cell
infect
addit
numer
studi
shown
cell
cultur
extrem
use
experiment
model
extend
influenza
virushost
interact
studi
screen
potenti
antivir
particular
polar
cell
shown
valuabl
model
studi
influenza
viru
support
viral
replic
type
ifn
respons
similarli
primari
human
bronchial
epitheli
hbe
cell
cultur
system
differenti
primari
epitheli
cell
human
like
hbe
cell
recapitul
close
morpholog
featur
human
upper
airway
provid
less
conveni
reproduc
model
studi
influenza
viru
experi
passag
donor
variat
induc
variabl
differenti
phenotyp
studi
use
cell
cultur
rapidli
character
emerg
viru
compar
respons
sever
avian
human
influenza
virus
perform
silico
screen
potenti
antivir
believ
data
set
valuabl
resourc
studi
influenza
virus
two
ongo
studi
profil
mous
macaqu
pulmonari
respons
infect
j
morrison
l
josset
n
tchitchek
j
chang
j
belser
tumpey
g
katz
submit
public
e
de
wit
rasmussen
f
feldmann
bushmak
c
martellaro
e
haddock
okumura
proll
j
chang
gardner
g
katz
v
j
munster
submit
public
importantli
found
signific
number
drug
predict
revers
cell
respons
includ
minocyclin
jak
inhibitor
also
predict
revers
mous
macaqu
pulmonari
respons
infect
morrison
et
al
submit
demonstr
conserv
function
respons
model
conclus
highthroughput
profil
cellular
respons
infect
comparison
avian
iav
season
human
viru
reveal
induc
specif
respons
respons
common
avian
human
iav
transcriptom
profil
similar
indic
potenti
human
adapt
evolut
toward
respons
human
iav
could
survey
novel
isol
analysi
point
sever
fdaapprov
drug
includ
minocyclin
potenti
drug
would
import
explor
vivo
three
avianorigin
iav
isol
fatal
human
case
season
human
viru
use
studi
viru
stock
grown
allanto
caviti
embryon
hen
egg
h
avianorigin
iav
h
viru
allanto
fluid
multipl
egg
pool
clarifi
centrifug
aliquot
store
viru
titer
determin
plaqu
assay
previous
describ
research
avian
virus
conduct
biosafeti
level
contain
includ
enhanc
requir
us
depart
agricultur
select
agent
program
http
human
bronchial
epitheli
cell
line
origin
deriv
subbronchi
epithelium
lung
adenocarcinoma
atcc
cell
grown
previous
describ
confluent
monolay
polar
cell
achiev
stabl
transepitheli
resist
infect
apic
moi
incub
monolay
wash
remov
nonadher
viru
ml
minim
essenti
mediumbovin
serum
albumin
membsa
ad
apic
basolater
reservoir
cell
left
durat
experi
rna
extract
iav
mockinfect
cell
quadrupl
perform
previous
describ
probe
label
microarray
slide
hybrid
biolog
replic
perform
use
sureprint
human
gene
express
microarray
agil
technolog
accord
manufactur
instruct
slide
scan
agil
dna
microarray
scanner
model
use
xdr
set
raw
imag
analyz
use
agil
featur
extract
softwar
program
version
extract
raw
data
background
correct
use
normexp
method
offset
quantil
normal
use
limma
softwar
packag
r
environ
replic
probe
mean
summar
probe
requir
pass
agil
qualiti
control
qc
flag
gisfound
giswellabovebg
gissatur
gisfeatnonunifol
gisfeatpopnol
replic
least
one
infect
time
point
probe
pass
qc
filter
sampl
valu
calcul
differ
data
sampl
averag
data
timematch
mock
microarray
annot
retriev
geo
data
bank
geo
access
differenti
express
determin
compar
iavinfect
replic
timematch
mock
base
linear
model
fit
probe
use
r
softwar
packag
limma
criteria
differenti
express
absolut
log
q
valu
calcul
use
moder
test
subsequ
benjaminihochberg
correct
control
fals
discoveri
rate
fdr
associ
result
viral
condit
gene
classifi
downregul
throughout
infect
found
significantli
downregul
least
one
time
point
gene
found
downregul
differ
time
point
classifi
gene
transient
express
binari
de
matrix
column
per
viral
treatment
gene
downregul
transient
gene
valu
equal
de
de
use
cluster
de
gene
cluster
euclidian
distanc
constant
height
cut
hierarch
cluster
dendrogram
visual
transcript
similar
sampl
space
euclidian
distanc
calcul
transcriptom
normal
data
nonmetr
multidimension
scale
md
perform
use
mass
softwar
packag
r
bioconductor
program
map
distanc
space
minim
loss
inform
evalu
kruskal
stress
biolog
replic
condit
link
convex
hull
ie
polygon
use
function
chull
r
pearson
correl
coeffici
spearman
correl
coeffici
total
euclidean
distanc
total
manhattan
distanc
use
estim
similar
gene
express
profil
iav
mockinfect
sampl
averag
distanc
condit
calcul
arithmet
mean
distanc
biolog
replic
function
analysi
statist
signific
gene
express
chang
perform
use
ingenu
pathway
knowledg
base
ipa
ingenu
system
gene
set
enrich
analys
righttail
fisher
exact
test
use
calcul
p
valu
determin
probabl
biolog
function
assign
data
set
due
chanc
alon
enrich
score
calcul
ipa
use
probe
pass
qc
filter
background
data
set
upstream
regul
analysi
use
predict
regul
infer
activ
state
base
prior
knowledg
expect
effect
regul
known
target
gene
accord
ipa
databas
z
score
calcul
determin
whether
gene
express
chang
known
target
regul
consist
expect
literatur
z
score
chang
anticorrel
literatur
z
score
predict
potenti
antivir
queri
ipa
databas
list
de
gene
time
point
iav
select
molecul
annot
chemic
drug
biolog
drug
inhibitor
inhibitor
z
score
least
time
point
posit
z
score
time
point
confirm
whether
drug
identifi
ipa
induc
signatur
opposit
induc
iav
use
publicli
avail
connect
map
cmap
databas
build
cmap
collect
genomewid
transcript
data
cultur
human
cell
treat
differ
compound
use
list
de
gene
downregul
time
point
viral
condit
limit
top
downregul
gene
list
contain
higher
number
gene
agil
probe
map
affymetrix
probe
set
use
biomart
id
convert
tool
order
queri
cmap
databas
ten
drug
potenti
antivir
identifi
ipa
found
cmap
databas
analyz
permut
result
drug
consist
mean
cmap
score
enrich
score
ie
score
posit
neg
relationship
drug
viral
signatur
depict
network
use
cytoscap
softwar
circular
layout
minocyclin
hydrochlorid
sigma
ribavirin
sigma
dissolv
dimethyl
sulfoxid
dmso
assay
minocyclin
cytotox
cell
grown
plate
treat
increas
concentr
minocyclin
h
incub
reagent
roch
h
micropl
spectrophotomet
use
measur
absorb
sampl
nm
nm
refer
wavelength
antivir
assay
polar
cell
treat
drug
h
infect
moi
h
inocul
wash
away
cell
incub
drug
durat
experi
hpi
apic
supernat
infect
cell
collect
titer
determin
experi
perform
triplic
raw
microarray
data
deposit
ncbi
gene
express
omnibu
access
geo
seri
access
number
addit
normal
matrix
express
valu
util
studi
found
http
viromicswashingtonedu
